Utilize este identificador para referenciar este registo: http://hdl.handle.net/10400.16/2247
Título: Clinical implications of anti-HLA antibodies testing in kidney transplantation
Autor: Malheiro, J.
Tafulo, S.
Palavras-chave: allosensitization,
cell‑based crossmatches
donor‑specific antibodies
kidney transplantation
solid‑phase immunoassays
Data: 2018
Editora: Sociedade Portuguesa de Nefrologia
Citação: Port J Nephrol Hypert 2018; 32(1): 42-51
Resumo: Alloantibodies against donor human leukocyte antigens (HLA), termed as donor‑specific antibodies (DSA), are one of the most important factors for both early and late kidney allograft dysfunction. In the past, these antibodies were mainly detected through cell‑based crossmatch tests. Recently, new techniques such as solid phase immunoassays (SPI) have revealed these antibodies in patient sera with a high degree of detail, previously unimaginable. They have allowed us to accurately determine recipients’ allosensitization status, improve pre‑transplant risk assessment with a potential donor and post‑transplant alloimmune monitoring. However, the high sensitivity of these new assays has also created areas of uncertainty about their clinical impact. In the pre‑transplant setting, the presence of preformed DSA has been associated with an increased risk of antibody‑mediated rejection (AMR) and subsequent allograft loss. Nevertheless, several studies have shown that not all DSA are deleterious. Hence, understanding the clinical correlations of DSA characteristics, namely strength, HLA class, complement‑fixing ability or IgG subclasses, is paramount for an adequate stratification of the immunological risk at transplant. Furthermore, given that the number of allosensitized patients on waiting lists is increasing, the added information from these new SPI is essential to improve their chance of being transplanted with an admissible immunological risk. After transplantation, the appearance of de novo DSA (dnDSA) has also been associated with a deleterious effect on kidney allograft survival. Moreover, it has been acknowledged that a majority of late allograft failures are caused by alloantibody‑driven injury. The current challenges, in this setting, are determining cost‑effective DSA screening protocols and understanding which patients could benefit from specific interventions. Furthermore, although therapeutic strategies to control antibody‑induced damage remain limited, the longitudinal surveillance of dnDSA emergence and the clinical correlations of their characteristics will play a crucial role in the improvement of late kidney allograft survival.
Peer review: yes
URI: http://hdl.handle.net/10400.16/2247
ISSN: 2183-1289
Versão do Editor: http://www.spnefro.pt/rpnh/browse_all_issues/67_volume_32_number_1
Aparece nas colecções:SNEF - Artigos publicados em revistas não indexadas na Medline

Ficheiros deste registo:
Ficheiro Descrição TamanhoFormato 
Clinical implications of anti-HLA antibodies.pdf345,88 kBAdobe PDFVer/Abrir

FacebookTwitterDeliciousLinkedInDiggGoogle BookmarksMySpace
Formato BibTex MendeleyEndnote Degois 

Todos os registos no repositório estão protegidos por leis de copyright, com todos os direitos reservados.